First Affirmative Financial Network Invests $242,000 in Hologic, Inc. (NASDAQ:HOLX)

First Affirmative Financial Network purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 2,973 shares of the medical equipment provider’s stock, valued at approximately $242,000.

Other hedge funds also recently added to or reduced their stakes in the company. Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Hologic by 257.7% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,826 shares of the medical equipment provider’s stock valued at $230,000 after buying an additional 2,036 shares during the last quarter. Boston Common Asset Management LLC grew its position in Hologic by 0.3% in the 3rd quarter. Boston Common Asset Management LLC now owns 306,665 shares of the medical equipment provider’s stock valued at $24,981,000 after acquiring an additional 831 shares during the last quarter. Wedmont Private Capital increased its stake in Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock worth $361,000 after purchasing an additional 162 shares during the period. Marcum Wealth LLC bought a new stake in shares of Hologic during the third quarter worth $202,000. Finally, FCF Advisors LLC purchased a new stake in shares of Hologic during the third quarter valued at $1,469,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

HOLX opened at $79.81 on Friday. The firm has a market capitalization of $18.63 billion, a PE ratio of 40.72, a price-to-earnings-growth ratio of 2.89 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The business’s 50-day moving average is $81.06 and its two-hundred day moving average is $77.58. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLXGet Free Report) last issued its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the firm earned $0.93 EPS. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. Research analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Brandon Schnittker sold 476 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at $310,415.85. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Leerink Partners lowered their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, September 17th. Evercore ISI lifted their target price on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Finally, Mizuho increased their price target on Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.50.

Check Out Our Latest Report on Hologic

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.